STELLAR BIOTECHNOLOGIES, INC. (NASDAQ:SBOT) Files An 8-K Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
Item 5.03. Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year.

On April 9, 2018 (the “Effective Date”), Stellar Biotechnologies, Inc. (the “Company”) filed a Notice of Alteration with the British Columbia Registry Services to amend (the “Amendment”) the Company’s Notice of Articles and Articles (the “Articles”). to the Amendment, the Articles were revised to add Part 26, which creates a class of an unlimited number of preferred shares without par value (the “Preferred Shares”), which Preferred Shares may be designated and issued in one or more series in the future, with such rights, preferences and privileges as determined by the Company’s Board of Directors (the “Board”). Except for such rights relating to the election of directors on a default in payment of dividends as may be attached to any series of the Preferred Shares by the Board, or in connection with convertible Preferred Shares, the holders of Preferred Shares shall not be entitled as such to receive notice of, or to attend or to vote at any general meeting of shareholders of the Company. As previously disclosed on a Current Report on Form 8-K filed with the Securities and Exchange Commission on April 3, 2018, the Amendment was approved at the Company’s Annual Meeting of Shareholders held on March 27, 2018. The Amendment to the Articles is effective as of the Effective Date.

The foregoing description of the Amendment does not purport to be complete and is qualified in its entirety by reference to the Articles, as amended by the Amendment, that are attached hereto as Exhibit 3.1 and incorporated by reference herein.

(d) Exhibits

Stellar Biotechnologies, Inc. Exhibit
EX-3.1 2 tv490804_ex3-1.htm EXHIBIT 3.1   Exhibit 3.1   BUSINESS CORPORATIONS ACT   AMENDED AND RESTATED   ARTICLES OF   Stellar biotechnologies,…
To view the full exhibit click here

About STELLAR BIOTECHNOLOGIES, INC. (NASDAQ:SBOT)

Stellar Biotechnologies, Inc. is a biotechnology company. The Company is engaged in the aquaculture, research and development, manufacture and commercialization of Keyhole Limpet Hemocyanin (KLH). KLH is an immune-stimulating protein. KLH can be used as an active pharmaceutical ingredient (API) and combined with a disease-targeting agent to create immunotherapies for the treatment of a range of diseases. The Company’s core business is developing and commercializing Keyhole Limpet Hemocyanin for use in immunotherapy and immunodiagnostic applications. The Company’s Stellar KLH product offerings include Stellar KLH protein for conjugation and as carrier molecule in immunotherapy development; Stellar KLH protein and enzyme-linked immunosorbent assay (ELISA) test kits for immune function testing, and Custom KLH formulations, adjuvants, conjugations and fill finishes for preclinical research and drug development applications.